<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04153292</url>
  </required_header>
  <id_info>
    <org_study_id>2018-19</org_study_id>
    <nct_id>NCT04153292</nct_id>
  </id_info>
  <brief_title>The ENCIRCLE Trial</brief_title>
  <acronym>ENCIRCLE</acronym>
  <official_title>SAPIEN M3 System Transcatheter Mitral Valve Replacement Via Transseptal Access</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edwards Lifesciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will establish the safety and effectiveness of the SAPIEN M3 System in subjects&#xD;
      with symptomatic, at least 3+ mitral regurgitation (MR) for whom commercially available&#xD;
      surgical or transcatheter treatment options are deemed unsuitable.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective single-arm, multicenter study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 12, 2020</start_date>
  <completion_date type="Anticipated">February 2028</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Non-hierarchical composite of death and heart failure rehospitalization</measure>
    <time_frame>1 year</time_frame>
    <description>Number of subjects with death and/or heart failure rehospitalization</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in NYHA functional class compared to baseline</measure>
    <time_frame>1 year</time_frame>
    <description>New York Heart Association (NYHA) functional classification of heart failure is based on how much a patient is limited during physical activity. The rating ranges from I-IV. I = no limitations of physical activity; II = slight limitations of physical activity, ordinary physical activity results in fatigue, palpitation, shortness of breath; III = marked limitations of physical activity, less than ordinary activity causes fatigue, palpitation, or shortness of breath; IV = unable to carry on any physical activity without discomfort, symptoms of heart failure at rest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in KCCQ Overall Score compared to baseline</measure>
    <time_frame>1 year</time_frame>
    <description>The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. An overall summary score can be derived from the physical function, symptom (frequency and severity), social function and quality of life domains. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in MR compared to baseline</measure>
    <time_frame>1 year</time_frame>
    <description>Number of subjects with improved MR compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in LVEDVi compared to baseline</measure>
    <time_frame>1 year</time_frame>
    <description>Number of subjects with decreased left ventricular end-diastolic volume index (LVEDVi) compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Mitral Regurgitation</condition>
  <condition>Mitral Valve Insufficiency</condition>
  <arm_group>
    <arm_group_label>TMVR - Main Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects for whom commercially available surgical or transcatheter treatment options are deemed unsuitable will have transcatheter mitral valve replacement (TMVR).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TMVR - Failed TEER Registry</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who have had an attempted but failed transcatheter edge-to-edge repair (TEER) procedure will have TMVR.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SAPIEN M3 valve and dock</intervention_name>
    <description>During the procedure a SAPIEN M3 dock and a SAPIEN M3 valve will be implanted via transseptal approach.</description>
    <arm_group_label>TMVR - Failed TEER Registry</arm_group_label>
    <arm_group_label>TMVR - Main Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 years of age or older&#xD;
&#xD;
          2. MR ≥ 3+&#xD;
&#xD;
          3. NYHA functional class ≥ II&#xD;
&#xD;
          4. Per the Heart Team, commercially available surgical or transcatheter treatment options&#xD;
             are deemed unsuitable due to clinical, anatomic or technical considerations.&#xD;
&#xD;
          5. Subject's heart failure management has been optimized based on subject characteristics&#xD;
             and applicable guidelines, and stable for at least 30 days prior to enrollment.&#xD;
&#xD;
          6. The subject or subject's legal representative has been informed of the nature of the&#xD;
             study, agrees to its provisions and has provided written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Mitral/cardiac anatomy that would preclude appropriate delivery and deployment of the&#xD;
             SAPIEN M3 dock or valve&#xD;
&#xD;
          2. Inappropriate anatomy for femoral introduction and delivery of the SAPIEN M3 dock and&#xD;
             valve&#xD;
&#xD;
          3. Presence of any device that will contact or interfere with the SAPIEN M3 System during&#xD;
             delivery or after implantation&#xD;
&#xD;
          4. Left ventricular ejection fraction &lt;30%&#xD;
&#xD;
          5. Severe right ventricular dysfunction&#xD;
&#xD;
          6. Need for aortic, tricuspid or pulmonic valve intervention within the next 12 months&#xD;
&#xD;
          7. History of heart transplant&#xD;
&#xD;
          8. Cardiac imaging evidence of intracardiac mass, thrombus or vegetation&#xD;
&#xD;
          9. Active bacterial endocarditis within 180 days of the procedure&#xD;
&#xD;
         10. Hemodynamic instability requiring inotropic or mechanical support within 30 days of&#xD;
             the procedure&#xD;
&#xD;
         11. Myocardial infarction within 30 days of the procedure&#xD;
&#xD;
         12. Clinically significant untreated coronary artery disease requiring revascularization&#xD;
&#xD;
         13. Any percutaneous cardiovascular intervention, cardiovascular surgery, or carotid&#xD;
             surgery within 30 days of the procedure&#xD;
&#xD;
         14. Stroke or transient ischemic attack within 90 days of the procedure&#xD;
&#xD;
         15. Irreversible, severe pulmonary hypertension&#xD;
&#xD;
         16. Chronic obstructive pulmonary disease requiring home oxygen therapy or chronic&#xD;
             outpatient oral steroid use&#xD;
&#xD;
         17. Renal insufficiency or receiving renal replacement therapy&#xD;
&#xD;
         18. Liver disease&#xD;
&#xD;
         19. Planned surgery within the next 12 months&#xD;
&#xD;
         20. Inability to tolerate or a medical condition precluding treatment with antithrombotic&#xD;
             therapy, including heparin administration during the procedure&#xD;
&#xD;
         21. Active infection requiring current antibiotic therapy&#xD;
&#xD;
         22. Active SARS-CoV-2 infection (Coronavirus-19 [COVID-19]) or previously diagnosed with&#xD;
             COVID-19 with sequelae that could confound endpoint assessments&#xD;
&#xD;
         23. Leukopenia, anemia, thrombocytopenia, history of bleeding diathesis or coagulopathy or&#xD;
             hypercoagulable states&#xD;
&#xD;
         24. Refusal of blood products&#xD;
&#xD;
         25. Female who is pregnant or lactating&#xD;
&#xD;
         26. Estimated life expectancy &lt;12 months due to non-cardiac conditions&#xD;
&#xD;
         27. Participating in another investigational drug or device study that has not reached its&#xD;
             primary endpoint&#xD;
&#xD;
         28. Subject considered to be part of a vulnerable population&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Webb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Paul's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mayra Guerrero, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Daniels, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>California Pacific Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Edwards THV Clinical Affairs</last_name>
    <phone>+1 (949) 250-2500</phone>
    <email>THV_CT.gov@Edwards.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>TMC Healthcare</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UC Health Northern Colorado (Medical Center of the Rockies)</name>
      <address>
        <city>Loveland</city>
        <state>Colorado</state>
        <zip>80538</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Piedmont Healthcare</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Vincent Heart Center of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Research Institute of Kansas (CRIOK)</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medstar Union Memorial Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Henry Ford</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CentraCare</name>
      <address>
        <city>Saint Cloud</city>
        <state>Minnesota</state>
        <zip>56303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Robert Wood Johnson University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mount Carmel East Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oklahoma Heart Institute</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Alleghany General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Austin Heart</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>HCA Houston Healthcare Medical (SCRI)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UT Memorial Hermann</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sentara Norfolk</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Pauls</name>
      <address>
        <city>Vancouver</city>
        <zip>V6E 1M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>November 4, 2019</study_first_submitted>
  <study_first_submitted_qc>November 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2019</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

